Neurology CME: Top 10 Free Online Courses in Q1 2023

myCME, the leader in free medical education, offers a host of courses across all neurological diseases. Access the entire library of Neurology CME and CE for Free.

The top neurology CME available right now on www.myCME.com featuring courses on  strokes, seizures, headaches, Alzheimer’s disease and more.

Neurology CME Course 1: Addressing the Challenges of Telemedicine in MS

Program Description

Through a comprehensive education program on telemedicine in MS, our sincere hope is that both patients and clinicians can work together to make patients’ lives better and improve clinical outcomes.

Educational Objectives

Upon completion, participants should be able to:

• Apply best practices for the use of digital technologies for telemedicine visits
• Perform a neurological physical examination through telemedicine based on current best practices
• Incorporate knowledge of the key barriers in equitable healthcare in telemedicine-based MS practice

Intended Audience

This activity is intended to meet the educational needs of healthcare providers treating patients with MS.

Commercial Supporter

This activity is supported by educational grants from Genentech and Novartis Pharmaceuticals Corporation.

Maximum Credits:

• 1.00 / AMA PRA Category 1 Credit^TM

Expires: June 7, 2023

---

Neurology CME Course 2: Fresh Insights From the Alzheimer’s Association International Conference 2022

Program Description

If you weren’t at AAIC or you would like to revisit it, this activity shares conference highlights and, over six modules, translates this information into what it can mean for the future of AD care.

Educational Objectives

Upon completion, participants should be able to:

• Summarize new findings exploring the evolving epidemiology of AD
• Select appropriate tools and techniques, including biomarkers, in the early detection of AD
• Identify early symptomatic stages of AD for timely and accurate diagnosis
• Discuss emerging efficacy and safety data for new AD disease modifying therapies

Intended Audience

This activity is intended for neurology and psychiatry specialists. Others involved in the care of patients with dementia may also benefit from this education.

Commercial Supporter

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Maximum Credits:

• 1.50 / AMA PRA Category 1 Credit(s)^TM
• 1.50 / ABPN MOC Part II Credits

Expires: September 21, 2023

---

Neurology CME Course 3: Cases in Diagnosis and Treatment, A Case-Based Roadmap for Improved Patient Outcomes in Multiple Sclerosis

Program Description

Multiple sclerosis (MS) is a chronic, progressive, and disabling inflammatory neurologic condition that causes more disability than any other nontraumatic neurologic condition. Early diagnosis, treatment, and monitoring of disease progression are fundamental to optimizing management of patients with MS. Here, we present an online learning module that covers key principles in all phases of management, with a focus on up-to-date and evidence-based principles of providing high-quality care.

Educational Objectives

Upon completion, participants should be able to:

• Select a treatment plan for a patient with MS that is consistent with the state-of-the-art in MS care
• Recognize a patient with a highly active MS presentation or a poor prognosis
• Select a treatment based on its demonstrated clinical efficacy and a patient’s MS presentation
• Recognize adverse event prevention, monitoring, and/or mitigation strategies

Intended Audience

This activity was developed for neurologists, physician assistants, nurse practitioners, and allied healthcare professionals who diagnose and manage patients with multiple sclerosis (MS).

Commercial Supporter

This activity is supported by educational grants from Genentech, a member of the Roche Group, and Novartis.

Maximum Credits:

• 1.00 / AMA PRA Category 1 Credit^TM
• 1.00 / ANCC Contact Hour

Expires: September 9, 2023

---

Neurology CME Course 4: Why Now? The New Paradigm and Rising Role of Nuclear Medicine in Alzheimer’s Disease

Program Description

This symposium, originally held in conjunction with the 2022 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, is designed to highlight the perspectives of noted experts on just how the role of NM is evolving in AD. Using recent data and clinical experience, the faculty will guide learners through recommended NM practices and reinforce the foundational knowledge required to adopt the skills needed for deeper involvement in AD management going forward.

Educational Objectives

Upon completion, participants should be able to:

• Evaluate the evolving role of neurobiology in the modern management of AD to ascertain how and where NM will be most valuable in the coming years.
• Recognize the variable uses of and key techniques involved in evaluation of amyloid PET for diagnosis and therapeutic management of AD to determine how and for whom this test is best utilized.
• Appraise the rising importance of tau PET imaging for AD prognosis and its role in therapeutic trials to determine its potential clinical utility.
• Identify the current status of and investigated outcomes with new and emerging amyloid-targeting disease modifying therapies designed to treat AD to determine their potential role in clinical practice.

Intended Audience

This activity is intended for nuclear medicine physicians, radiologists, neurologists, technologists, and other healthcare professionals involved in the diagnosis and long-term management of patients with AD.

Commercial Supporter

This activity is supported by an educational grant from Lilly.

Maximum Credits:

• 1.00 / AMA PRA Category 1 Credit^TM

Expires: July 19, 2023

---

Neurology CME Course 5: Improving Awareness of the Differences in Narcolepsy and Novel Strategies for Treatment

Program Description

Join expert faculty in this OnDemand initiative as they discuss effective tools and strategies to improve the accurate and early detection of narcolepsy, as well as the latest evidence on optimal treatment strategies to achieve sustained benefits by improving clinical outcomes and facilitating adherence.

Educational Objectives

Upon completion, participants should be able to:

• Recognize the varied presentation of narcolepsy diagnosis.
• Differentiate the clinical, functional, and psychosocial impact of NT1 versus NT2
• Evaluate the latest safety and efficacy data on novel and emerging strategies to reduce the burden and impact of EDS and cataplexy in adults with narcolepsy.

Intended Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in sleep, pulmonology, psychiatry, neurology and/or primary care

Commercial Supporter

Supported by an educational grant from Avadel CNS Pharmaceuticals, LLC.

Maximum Credits:

• 1.50 / AMA PRA Category 1 Credit(s)^TM
• 1.50 / AMA PRA Category 1 Credit(s)^TM/ ABIM MOC Point(s)
• 1.50 / AAPA Category 1 CME Credits
• 1.50 / CNE Contact Hour(s)
• 1.50 / CE for Pharmacists
• 1.50 / CE for Psychologists

Expires: June 8, 2023

---

Neurology CME Course 6: Safe, Effective, and Personalized Treatment for OSA-related EDS

Program Description

Join Drs. Richard Bogan and Paula Schweitzer as they discuss case 2 of this 3-part CMEO BriefCase series and provide guidance on the nuances of personalizing treatment selection and strategies to monitor treatment effectiveness to provide safe, effective, long-term care.

Educational Objectives

Upon completion, participants should be able to:

• Position treatment strategies for OSA-related EDS based on individual patient profiles.

Intended Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in sleep, pulmonology, psychiatry, neurology and/or primary care

Commercial Supporter

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

Maximum Credits:

• 0.50 / AMA PRA Category 1 Credit(s)^TM
• 0.50 / AMA PRA Category 1 Credit(s)^TM /ABIM MOC Point(s)
• 0.50 / AAPA Category 1 CME Credits
• 0.50 / CNE Contact Hour(s)
• 0.50 / CE for Pharmacists

Expires: May 12, 2023

---

Neurology CME Course 7: Modern Tools to Assist Navigating Prognosis, Monitoring, and Therapeutic Decision-Making in the Long-Term Management of Multiple Sclerosis

Program Description

This symposium, originally held in conjunction with the 2022 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, is designed to elucidate the perspectives of noted experts on existing and rising indicators of MS prognosis and/or disease activity (e.g., serum biomarkers, lesion topography). During the program, invited faculty advocate for their preferred biomarkers and/or clinical indicators and why they may represent the future of successful disease management. By gaining understanding of exactly how and why these factors should (or should not) be considered, clinicians may better navigate and optimize available tools and strategies for their own patients with MS..

Educational Objectives

Upon completion, participants should be able to:

• Assess the relative roles of existing predictors/indicators of disease progression to guide the prioritization of these factors in proactive assessment of patient changes.
• Appraise the utility of clinical and radiologic assessments of disease progression to select the most sensitive and clinically appropriate monitoring tools that will not disrupt current workflow.
• Analyze the influence of prognostic factors and clinical indicators on treatment initiation and switching strategies to optimize therapeutic decision-making and maximize patient outcomes.

Intended Audience

The target audience for this activity includes neurodegenerative disease specialists, general neurologists, nurse practitioners, physician assistants, registered nurses, and other healthcare professionals involved in the diagnosis and long-term management of patients with MS.

Commercial Supporter

This activity is supported by an educational grant from Genentech, A Member of the Roche Group.

Maximum Credits:

• 1.50 / AMA PRA Category 1 Credits^TM
• 1.50 / ANCC Contact Hours

Expires: August 9, 2023

---

Neurology CME Course 8: Gene Therapy and the Future of DMD Treatment

Program Description

The three gene therapy treatments in clinical trials differ in vector, promoter, and transgene. Learn what these components are and how gene therapy works in boys with Duchenne Muscular Dystrophy (DMD). Experts will review the latest results from the clinical trials and show functional data demonstrating the potential for gene therapy to slow disease progression. Safety and efficacy data and which patients may be eligible for this treatment is also discussed.

Educational Objectives

Upon completion, participants should be able to:

• Review the key components of gene therapy for DMD, including vectors, promoters, and transgene constructs
• Assess the prospective functional benefits of gene therapies in DMD and their potential to slow disease progression
• Evaluate the latest results from clinical trials for gene therapies in DMD

Intended Audience

Neurology and pediatric physicians and other clinical staff who are involved in the identification, diagnosis, treatment, and management of patients with DMD.

Commercial Supporter

This activity is supported by an educational grant from Sarepta Therapeutics

Maximum Credits:

• 1.00 / AMA PRA Category 1 Credit^TM

Expires: December 13, 2023

---

Neurology CME Course 9: Addressing Key Challenges and Strategic Solutions in the Use of Botulinum Toxin for Spasticity and Dystonia

Program Description

Using recent data and clinical experience, the faculty will highlight the “Top 5” critical issues they see in clinical practice surrounding the use of BoNT therapy for spasticity and dystonia.

Educational Objectives

Upon completion, participants should be able to:

• Review the variable considerations (e.g., indication, dosing, pharmacological properties) that influence the choice to utilize BoNT and/or differentiate approved toxins to better customize the current integration of these agents into routine practice
• Examine strategies to identify muscle injection sites and patterns, including the evaluation of individual postures and use of guidance methods (e.g., US) to improve the accurate delivery of BoNT treatment
• Discuss expert approaches to identifying sources of inadequate- or non-response to BoNT to determine the optimal adjustments to technique and/or treatment strategy needed to maximize outcomes for individual patients

Intended Audience

The target audience for this initiative includes physiatrists, general neurologists, nurse practitioners, physician assistants, and other healthcare professionals involved in the diagnosis and long-term management of patients with spasticity and dystonia.

Commercial Supporter

This activity is supported by an educational grant from AbbVie.

Maximum Credits:

• 0.75 / AMA PRA Category 1 Credit^TM

Expires: September 14, 2023

---

Neurology CME Course 10: Cases in Diagnosis and Treatment, A Case-Based Roadmap for Improved Patient Outcomes in Multiple Sclerosis / Study Companion

Program Description

Multiple sclerosis (MS) is a chronic, progressive, and disabling inflammatory neurologic condition that causes more disability than any other nontraumatic neurologic condition. Early diagnosis, treatment, and monitoring of disease progression is fundamental to optimizing management of patients with MS. Join Edward Fox, MD, PhD, and Matthew Schindler, MD, PhD, in an interactive case-based roadmap for improved outcomes in patients with MS. In addition to addressing diagnostic challenges, Drs. Fox and Schindler share their insights into integrating advances in the pharmacologic treatment of patients with MS, focusing on the safety and efficacy of targeted therapies.

Educational Objectives

Upon completion, participants should be able to:

• Apply the diagnostic criteria and diagnostic algorithms to diagnose a patient with MS
• Select a treatment plan for a patient with MS that is consistent with the state-of-the-art in MS care
• Recognize a patient with a highly active MS presentation or a poor prognosis
• Recognize adverse event prevention, monitoring, and/or mitigation strategies

Intended Audience

This activity is intended for neurologists, physician assistants, nurse practitioners, and allied healthcare professionals who diagnose and manage patients with MS.

Commercial Supporter

This activity is supported by educational grants from Genentech, a member of the Roche Group, and Novartis.

Maximum Credits:

• 1.00 / AMA PRA Category 1 Credit^TM
• 1.00 / ANCC Contact Hour

Expires: July 9, 2023

---

These neurology CME/CE courses, powered by myCME, are specialty-based courses, resources, and news tailored and curated for you.

Make sure to take advantage of these accredited free neurology CE and CME courses for your continuing education.